Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children

Giuseppe Grandy, Marcos Medina, Richard Soria, Carlos G Terán, Magdalena Araya, Giuseppe Grandy, Marcos Medina, Richard Soria, Carlos G Terán, Magdalena Araya

Abstract

Background: Evidence suggests that probiotics reduce rotavirus diarrhoea duration. Although there are several probiotic strains potentially useful, daily practice is often limited by the type and number of products locally available. In general, information about combined products is scarce. In this study we compare the effect of two probiotic products in the treatment of diarrhoea in children less than 2 years of age.

Methods: A Randomized double-blind controlled clinical trial in children hospitalized for acute rotavirus diarrhoea, in the Paediatric Centre Albina Patino, Cochabamba, Bolivia.Participants were children aged 1 - 23 months, who were randomly assigned to receive one of three treatments: Oral rehydration therapy plus placebo; Oral rehydration solution plus Saccharomyces boulardii; or Oral rehydration solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii. Sample size was 20 per group and the outcomes were duration of diarrhoea, of fever, of vomiting and of hospitalization.

Results: 64 cases finished the protocol. On admission, patients' characteristics were similar. Median duration of diarrhoea (p = 0.04) in children who received the single species product (58 hours) was shorter than in controls (84.5 hrs). Comparing children that received the single probiotic product and controls showed shorter duration of fever (18 vs 67 hrs) (p = 0.0042) and the mixed probiotic of vomiting (0 vs 42.5 hrs) (p = 0.041). There was no effect on duration of hospitalization (p = 0.31). When experimental groups were merged, statistical significance of changes increased (total duration of diarrhoea, fever and vomiting P = 0.025, P = 0.025 and P = 0.014, respectively).

Conclusions: Both products decreased the duration of diarrhoea compared to oral rehydration solution alone. This decrease was significant only for the single species product which also decreased the duration of fever. With the multiple species product there was no vomiting subsequent to the initiation of treatment. The quantity of probiotic bacteria needed for optimum treatment of gastroenteritis remains to be determined, particularly when multiple species are included in the product.Trial registration: ClinicalTrials.gov ID: NCT00981877Link: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol/sid/S0002653/selectaction/View/ts/2/uid/U0000N04

Trial registration: Clinical trials NCT ID: NCT00981877.

Figures

Figure 1
Figure 1
Flow Diagram. Flow of participants through trial.

References

    1. Wilhelmi I, Román E, Sánchez-Fauquier A. Viruses causing gastroenteritis. Clin Microbiol Infect. 2003;9:247–62. doi: 10.1046/j.1469-0691.2003.00560.x.
    1. Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis. 1998;177(1):13–7. doi: 10.1086/513808.
    1. de Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ. 1985;63(3):569–83.
    1. Panamerican Health Organization. Epidemiologic surveillance of diarrheal diseases due to rotavirus: Field guide. Washington, D.C.: OPS; 2007. (ISBN 92 75 11623 7)
    1. Kane M, Turcios R, Arvay M, García S, Bresee J, Glass J. The Epidemiology of Rotavirus Diarrhea in Latin America Anticipating Rotavirus Vaccine. Rev Panam Salud Publica. 2004;16(6):371–377. doi: 10.1590/S1020-49892004001200002.
    1. Ministerio de Salud y Deportes - Bolivia. Boletín informativo epidemiológico: Situación epidemiológica del rotavirus. Julio 2008.
    1. López E, Barrera F, Saavedra J, Cona E, Aguilera G. Rotavirus in the feces of children with acute diarrhea in Cochabamba, Bolivia. Rev Chil Pediatr. 1989;60(1):34–5.
    1. Romero C, Iniguez V. et al.Enfermedades Diarreicas Agudas Asociadas a Rotavirus. Rev Chil Pediatr. 2007;78(5):549–558. doi: 10.4067/S0370-41062007000500014.
    1. Samadi AR, Islam R, Huq MI. Replacement of intravenous therapy by oral rehydration solution in a large treatment centre for diarrhoea with dehydration. Bull World Health Organization. 1998;76(4):319–324.
    1. Koletzko S, Osterrieder S. Acute infectious diarrhea in children. Dtsch Arztebl Int. 2009;106(33):539–47. 11.
    1. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A. et al.Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007;335(7615):340. doi: 10.1136/bmj.39272.581736.55.
    1. Ozuah PO, Avner JR, Stein RE. Oral rehydration, emergency physicians, and practice parameters: a national survey. Pediatrics. 2002;109(2):259–61. doi: 10.1542/peds.109.2.259.
    1. Fontaine O, Gore SM, Pierce NF. Rice-based oral rehydration solution for treating diarrhoea. Cochrane Database Syst Rev. 2000. p. CD001264.
    1. Cucchiara S, Falconieri P, Di Nardo G, Parcelii MA, Dito L, Grandinetti A. New therapeutic approach in the management of intestinal disease: probiotics in intestinal disease in paediatric age. Dig Liver Dis. 2002;34(Suppl 2):S44–7. doi: 10.1016/S1590-8658(02)80163-3.
    1. Boirivant M, Strober W. The mechanism of action of probiotic. Cur Opin Gastroenterol. 2007;23(6):679–92. doi: 10.1097/MOG.0b013e3282f0cffc.
    1. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization; 2006.
    1. Thompson RG. A simple concentration method for the detection of parasitic ova and cysts in faeces. J Clin Pathol. 1972;25:546–547. doi: 10.1136/jcp.25.6.546.
    1. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25(5):516–9. doi: 10.1097/00005176-199711000-00005.
    1. Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains--a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23(2):247–53. doi: 10.1111/j.1365-2036.2006.02740.x.
    1. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust. 2008;188(5):304–8.
    1. Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008;78(2):214–6.
    1. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Saeed Shekhani M. et al.Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12(28):4557–60.
    1. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(1):44–7. doi: 10.1080/08035250410022521.
    1. Pant AR, Graham SM, Allen SJ. et al.Lactobacillus GG and acute diarrhoea in young children in the tropics. J Trop Pediatr. 1996;42(3):162–5. doi: 10.1093/tropej/42.3.162.
    1. Raza S, Graham SM, Allen SJ. et al.Lactobacillus GG promotes recovery from acute nonbloody diarrhoea in Pakistan. Ped Infect Dis J. 1995;14(2):107–111. doi: 10.1097/00006454-199502000-00005.
    1. Shornikova AV, Casas IA, Isolauri E. et al.Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24(4):399–404. doi: 10.1097/00005176-199704000-00008.
    1. Nitazoxanide VS, Terán C, Terán-Escalera C, Villarroel P. Nitazoxanide vs. Probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian Children. Int J Infect Dis. 2009;13:518–523. doi: 10.1016/j.ijid.2008.09.014.
    1. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004. p. CD003048.
    1. Szajewska H, Setty M, Mrukowicz J, Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr. 2006;42(5):454–75. doi: 10.1097/01.mpg.0000221913.88511.72.
    1. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children; a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(Suppl 2):S17–25. doi: 10.1097/00005176-200110002-00004.
    1. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol. 2008;42(Suppl 2):S53–7. doi: 10.1097/MCG.0b013e3181674087.
    1. Van Niel C, Feudtner C, Garrison MM. et al.Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109(4):678–84. doi: 10.1542/peds.109.4.678.
    1. Fang SB, Lee HC, Hu JJ. et al.Dose-depent effect of lactobacillus rhamnosus on quantitative reduction of faecal rotavirus shedding in children. J Trop Ped. 2009;55(4):297–301. doi: 10.1093/tropej/fmp001.
    1. Basu S, Chatterjee M, Ganguly S. et al.Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children, a randomized controlled trial. J Clin Gastroenterol. 2007;41(8):756–60. doi: 10.1097/01.mcg.0000248009.47526.ea.
    1. Reid G, Sanders ME, Gaskins HR. et al.New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol. 2003;37(2):105–118. doi: 10.1097/00004836-200308000-00004.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa